Not yet reviewed — this article is pending editorial review by Lyrea.
Citation noticeOur citation system is being overhauled
References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.
4-FPP
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Duration
Subjective Effects
Pharmacology
Interactions
An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.
Tolerance
Harm Potential
Toxicity
Inhibition of various Cytochrome P450 enzymes in the liver has been demonstrated, which may contribute to the substance's side-effect profile and potential for drug interactions.
Higher doses above the typical active range can cause migraine headaches and anxiety.
Muscle aches have been reported at higher doses.
Nausea and vomiting can occur at higher doses.
History & Culture
Legality
References
Source Pages
Further Reading
Antia U et al. - Interaction potential of party-pill piperazines with CYP450- Antia U et al. Interaction potential of party-pill piperazines with CYP450.
Arbo et al. - Piperazine compounds as drugs of abuse (Review)
EMCDDA: 4-Fluorophenylpiperazine profile- Nichols DE et al. - Serotonergic pharmacology of phenylpiperazines
- Nichols DE et al. Serotonergic pharmacology of p-fluorophenylpiperazine.
- Scherman D et al. - Molecular pharmacology of niaprazine and its metabolites
- Scherman D et al. Molecular pharmacology of niaprazine and its metabolites.
- Staack RF & Maurer HH - Metabolism of designer piperazines
- Staack RF & Maurer HH. Metabolism of designer piperazines.
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass reviewPending
Not yet reviewed — this article is pending editorial review by Lyrea.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes7 human edits · latest
Times are UTCNewest first
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 4-FPP article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.